Insider Transactions in Q2 2023 at Arcutis Biotherapeutics, Inc. (ARQT)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2023
|
Todd Franklin Watanabe Director |
BUY
Open market or private purchase
|
Direct |
1,463
+0.28%
|
$8,778
$6.38 P/Share
|
|
May 31
2023
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,463
+3.25%
|
$8,778
$6.38 P/Share
|
|
May 31
2023
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,830
-4.16%
|
$12,810
$7.8 P/Share
|
|
May 31
2023
|
Sue Jean Lin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+32.74%
|
-
|
|
May 31
2023
|
Patrick J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+33.49%
|
-
|
|
May 31
2023
|
Terrie Curran Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+33.49%
|
-
|
|
May 31
2023
|
Bhaskar Chaudhuri Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+0.51%
|
-
|
|
May 31
2023
|
Halley E Gilbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+33.49%
|
-
|
|
May 31
2023
|
Keith R Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+33.49%
|
-
|
|
May 31
2023
|
Neha Krishnamohan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+43.83%
|
-
|
|
May 31
2023
|
Howard G. Welgus Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+2.51%
|
-
|
|
May 27
2023
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+9.98%
|
-
|
|
Apr 17
2023
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
8,500
-4.88%
|
$110,500
$13.97 P/Share
|
|
Apr 17
2023
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+4.65%
|
$8,500
$1.68 P/Share
|
|
Apr 06
2023
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
8,500
-4.88%
|
$102,000
$12.01 P/Share
|
|
Apr 06
2023
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+4.65%
|
$8,500
$1.68 P/Share
|